PharmAust ready to trial monepantel on humans to fight motor neurone disease
PharmAust progresses flagship Monepantel drug in treating canine lymphoma and COVID-19
Monsoon Communications Twilight Webinar – November 2021
PharmAust AGM 2021
Virtual Investor Briefing – August 2021
Q-Wrapz: Oriel Morrison interviews Roger Aston, executive chairman of PharmAust Ltd (ASX:PAA)
PharmAust progresses flagship Monepantel drug in treating canine lymphoma and COVID-19
Epichem OHD Presentation – Waste To Fuels Technology
PharmAust Webinar – Feb 11th
PharmAust Limited AGM 2020
Auzbiz Interview with Dr Richard Mollard – September 2020
PAA awarded a grant for Phase I trial in Motor Neurone Disease
PharmAust confirms Monepantel’s anti-viral potential in the fight against COVID-19
Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
PharmAust Virtual Investor Briefing – June 2020
PAA Speech at Med-Tech & Healthcare Investors Night – July 2019
90 Seconds With Spark – PharmAust (ASX:PAA)
Dr Martine Keenan – CEO and Head of Drug Discovery Interview
Proactive Investors Interview with Dr Roger Aston, Executive Chairman of PharmAust (PAA)
PharmAust: New Drug Entering Phase 2 Trials Targeting Multiple Cancers
Interview on RedChip Money Report television program aired on Bloomberg the 2nd and 3rd of January 2016
PharmAust: Developing Targeted Cancer Therapy
Dave Gentry, host of “The RedChip Money Report”, interviews Dr. Roger Aston, Executive Chairman of PharmAust Ltd (ASX: PAA) as aired on Bloomberg TV.
PharmAust Presentation at RedChip’s February 2016 Conference
PharmAust presentation at the RedChip Global Online Microcap Conference on Thursday, February 11, 2016.